Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by United Asset Strategies Inc.

United Asset Strategies Inc. decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.6% during the 4th quarter, Holdings Channel reports. The fund owned 13,798 shares of the medical equipment provider’s stock after selling 2,754 shares during the quarter. United Asset Strategies Inc.’s holdings in Zimmer Biomet were worth $1,679,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in ZBH. Fairfield Bush & CO. purchased a new position in Zimmer Biomet in the first quarter valued at approximately $111,000. United Bank increased its stake in Zimmer Biomet by 4.1% in the first quarter. United Bank now owns 11,072 shares of the medical equipment provider’s stock valued at $1,416,000 after purchasing an additional 437 shares during the last quarter. Panagora Asset Management Inc. increased its stake in Zimmer Biomet by 153.9% in the first quarter. Panagora Asset Management Inc. now owns 9,803 shares of the medical equipment provider’s stock valued at $1,254,000 after purchasing an additional 5,942 shares during the last quarter. Aviva PLC increased its stake in Zimmer Biomet by 0.4% in the first quarter. Aviva PLC now owns 30,636 shares of the medical equipment provider’s stock valued at $3,918,000 after purchasing an additional 137 shares during the last quarter. Finally, Allianz Asset Management GmbH increased its stake in Zimmer Biomet by 11.2% in the first quarter. Allianz Asset Management GmbH now owns 41,816 shares of the medical equipment provider’s stock valued at $5,348,000 after purchasing an additional 4,224 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analysts Set New Price Targets

ZBH has been the topic of several recent analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 9th. Raymond James increased their price target on shares of Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Truist Financial raised their target price on shares of Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a research report on Friday, February 9th. Barclays raised their target price on shares of Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a research report on Monday, February 12th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $139.39.

Zimmer Biomet Trading Down 1.6 %

Zimmer Biomet stock opened at $122.07 on Wednesday. The stock has a market cap of $25.08 billion, a PE ratio of 24.96, a P/E/G ratio of 2.28 and a beta of 1.01. The stock has a 50-day moving average price of $126.59 and a 200 day moving average price of $119.09. Zimmer Biomet Holdings, Inc. has a 52 week low of $102.00 and a 52 week high of $149.25. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, beating the consensus estimate of $2.15 by $0.05. The company had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The firm’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.88 EPS. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet’s payout ratio is currently 19.63%.

Insider Transactions at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the business’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the sale, the vice president now owns 44,145 shares in the company, valued at approximately $5,677,929.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.70% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.